FDA revamps adverse event reporting guidance for Covid-19
The FDA on Thursday revised its guidance on postmarket adverse event reporting for medical products and dietary supplements during a pandemic to apply the guidance …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
